Cell Line Data Sheet for CHLA-32

Disease:	Primitive neuroectodermal tumor (PNET)
Phase of Therapy:	Diagnosis
Treatment:	None
Disease Stage:	
Gender:	Female
Age at diagnosis:	102 months
Race:	N/A
Age at sample collection:	N/A
Source of Culture:	Solid tumor
Primary Tumor Site:	
Date Established:	
EWS/FLI1 Status:	FLI1
p53 functionality:	Functional
Karyotype:	
Modal No:	

IC90 (DIMSCAN*):

Vincristine (ng/ml)	Melphalan (µg/ml)	Etoposide (ng/ml)	Rapamycin (ng/ml)
N/A	N/A	N/A	N/A

Growth Conditions: Please see Protocols section at https://www.cccells.org/protocols.php
5% CO_2, 20% O_2, 37.0°C

Media Formulation: Please see Protocols section at https://www.cccells.org/protocols.php
Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

Doubling Time: 99 hours

Growth Properties: Flat, epithelial cells and round cells, attached monolayer and suspended clumps

STR Profile: May be obtained at https://strdb.cccells.org/

Notes:

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.

Cell Line Data Sheet for CHLA-32

References:

1. Batra S, Reynolds CP, Maurer BJ. Fenretinide cytotoxicity for Ewing's sarcoma (ES) and primitive neuroectodermal Tumor (PNET) cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Research 64: 5415-5424, 2004. PubMed ID: 15289350 https://cancerres.aacrjournals.org/content/64/15/5415.long

Cell Line Data Sheet for CHLA-32

Cell Line Name: **CHLA-32**

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)